TIDMSAR
RNS Number : 1927Z
Sareum Holdings PLC
16 May 2019
(AIM: SAR) 16 May 2019
Sareum Holdings PLC
("Sareum" or the "Company")
Sareum notes that Sierra Oncology has provided an update on its
clinical data presentations at ASCO 2019 with SRA737 (a Chk1
inhibitor) in subjects with advanced cancer
Sareum Holdings plc (AIM: SAR), the specialist small molecule
drug development business, notes that Sierra Oncology (the licence
holder for Chk1 inhibitor SRA737) has provided further information
relating to presentations of preliminary clinical data from its
Phase 1/2 SRA737 monotherapy study and its Phase 1/2 study of
SRA737 in combination with low dose gemcitabine (SRA737+LDG) at the
upcoming 2019 Annual Meeting of the American Society of Clinical
Oncology (ASCO) in Chicago, IL, USA (31 May-4 June 2019).
Two abstracts (published late yesterday) will be presented in
poster presentations on Saturday, 1 June.
ASCO 2019 Poster Presentations
Title: A first-in-human phase I/II trial of SRA737 (a Chk1
Inhibitor) in subjects with advanced cancer
Abstract: 3094
Poster #: 86
Poster Session: Developmental Therapeutics and Tumor Biology
(Nonimmuno)
Date and Time: Saturday, 1 June, 8:00 - 11:00 am CT
Location: McCormick Place, Event room: Hall A
The published abstract can be accessed by clicking here and its
conclusions are as follows:
In this first-in-human trial of SRA737 monotherapy, the MTD
(maximum tolerated dose) was 1000 mg/day and based on overall
tolerability and PK (pharmacokinetics), the recommended Phase 2
dose is 800 mg/day. The successful enrolment of
prospectively-selected genetically-defined subjects will allow
response data to be correlated with genomic profiles hypothesized
to confer sensitivity to Chk1 inhibition.
Title: A phase I/II first-in-human trial of oral SRA737 (a Chk1
inhibitor) given in combination with low-dose gemcitabine in
subjects with advanced cancer
Abstract: 3095
Poster #: 87
Poster Session: Developmental Therapeutics and Tumor Biology
(Nonimmuno)
Date and Time: Saturday, 1 June, 8:00 - 11:00 am CT
Location: McCormick Place, Event room: Hall A
The published abstract can be accessed by clicking here and its
conclusions are as follows:
The combination of LDG and SRA737 has been well tolerated. This
first-in-human clinical study provides proof-of-concept that
sub-therapeutic LDG effectively potentiates SRA737. This novel
replication stress-targeted therapy warrants further evaluation in
genetically pre-defined solid tumors.
Both posters will be available on 1 June at
www.sierraoncology.com
Dr Nick Glover, President and CEO of Sierra Oncology, commented
"We look forward to presenting preliminary data for these
first-in-human studies of SRA737 and SRA737+LDG at ASCO, and to
discussing the potential opportunities for further advancement of
our differentiated Chk1 inhibitor that these clinical data
provide.
"The two studies have enrolled patients across a range of tumor
indications including a variety of prospectively selected genetic
contexts, allowing us to broadly survey the cancer landscape for
activity signals in response to administration of SRA737 alone and
in combination with non-cytotoxic low dose gemcitabine. These
preliminary data have also enabled us to correlate clinical
findings with tumor origin and genetic signature, ascertain whether
the exogenous induction of replication stress via low dose
gemcitabine can enhance SRA737's activity, and determine potential
next steps in the development path for SRA737."
SRA737 Analyst & Investor Event
In addition, Sierra Oncology will be hosting an Analyst and
Investor Event from 6:00 - 7:00 am CT on Monday, 3 June to discuss
these clinical findings and potential next steps in the development
strategy for SRA737. The event will feature presentations by two
distinguished oncologists:
-- Professor Johann de Bono, Regius Professor of Cancer
Research, Head of the Division of Clinical Studies and Professor in
Experimental Cancer Medicine at The Institute of Cancer Research
and The Royal Marsden NHS Foundation Trust; and
-- Dr Rebecca Kristeleit, Clinical Senior Lecturer and Honorary
Consultant Medical Oncologist at University College London (UCL)
Cancer Institute & UCLH Dept. of Oncology, a leading expert in
gynaecological malignancies.
Location: History event room, Marriot Marquis Hotel, 2121 S
Prairie Ave, Chicago, IL, USA. Event registration and webcast
information are available at www.sierraoncology.com, and an archive
of the presentation will be accessible after the event through the
Sierra Oncology website.
The full announcement from Sierra Oncology can be found by
clicking here.
For further information, please contact:
Sareum Holdings plc
Tim Mitchell 01223 497 700
WH Ireland Limited (Nominated Adviser)
Chris Fielding / James Sinclair-Ford 020 7220 1666
Hybridan LLP (Nominated Broker)
Claire Noyce 020 3764 2341
Citigate Dewe Rogerson (Media enquiries)
Shabnam Bashir/ Mark Swallow/ David
Dible 020 7638 9571
Notes for editors:
Sareum is a specialist drug development company delivering
targeted small molecule therapeutics, to improve the treatment of
cancer and autoimmune disease. The Company generates value through
licensing its candidates to international pharmaceutical and
biotechnology companies at the preclinical or early clinical trials
stage.
Sareum's leading clinical-stage programme, SRA737, a novel
Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed
Sierra Oncology, is in Phase 2 clinical trials targeting ovarian
and other advanced cancers. The key role of Chk1 in cancer cell
replication and DNA damage repair suggests that SRA737 may have
broad application as a targeted therapy in combination with other
oncology and immune-oncology drugs in genetically defined
patients.
Sareum is also advancing internal programmes focused on distinct
dual tyrosine kinase 2 (TYK2) /Janus kinase 1 (JAK1) inhibitors
through preclinical development as therapies for autoimmune
diseases (SDC-1801) and cancers (SDC-1802). TYK2 and JAK1 have
roles in pro-inflammatory responses in autoimmune diseases (e.g.
psoriasis, rheumatoid arthritis, inflammatory bowel diseases and
lupus) and tumour cell proliferation in certain cancers (e.g.
T-cell acute lymphoblastic leukaemia and some solid tumours). The
Company is targeting first human clinical trials in each indication
in 2020.
The Company also has an Aurora+FLT3 inhibitor targeting
haematological cancers, which is at the preclinical development
stage.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the ticker SAR. For further
information, please visit www.sareum.co.uk
- Ends -
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCXELLFKEFEBBV
(END) Dow Jones Newswires
May 16, 2019 02:01 ET (06:01 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2024 to May 2024
Sareum (LSE:SAR)
Historical Stock Chart
From May 2023 to May 2024